Integrated DNA Technologies (IDT) has announced a partnership with Elegen to enhance its DNA synthesis offerings, providing customers with access to both short and long DNA sequences.

As part of this collaboration, IDT customers will receive early access to Elegen's Enfinia Plasmid DNA service, which features clonal genes ranging from 5 kb to 15 kb, with a rapid turnaround time of as little as 10 business days.

Sandy Ottensmann, IDT's VP, highlighted the increasing demand from customers for long and complex DNA sequences, particularly for applications in cell and gene therapy, antibody development, and AI-driven projects.

Traditionally, DNA synthesis has been divided into short sequences, up to 300 bases, and long sequences, with the latter gaining importance for more complex applications.

The enzymatic DNA synthesis method employed by Elegen allows for the creation of long and intricate DNA sequences, addressing the growing needs of researchers.

Elegen's pricing remains competitive, with costs as low as $0.15 per base pair, ensuring affordability for customers.

IDT's decision to partner with Elegen was influenced by Elegen's strong market presence, proven track record, and competitive pricing, making this collaboration a strategic extension of IDT's synthetic biology portfolio.

In a related development, Ansa Biotechnologies recently achieved a significant milestone by synthesizing a 1,005 base DNA oligonucleotide, the longest reported in a single synthesis, aimed at potential gene therapy applications.